“We are very pleased to see this landmark, Phase III study published because it demonstrates the efficacy of abametapir lotion, which is currently pending FDA approval.”Lisa Jenkins VanLuvanee, Ph.D., Vice President of Research and Development at Facet Life Sciences
WAYNE, Pa. (PRWEB) September 19, 2018
Facet Life Sciences, a leading provider of development software and services for small and growing life sciences teams, today announced the publication of “Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation” in Pediatric Dermatology, the official journal of the Society for Pediatric Dermatology.
Lisa Jenkins VanLuvanee, Ph.D., Vice President of Research and Development at Facet Life Sciences, was one of seven authors who contributed to the publication. Dr. VanLuvanee commented, “We are very pleased to see this landmark, Phase III study published because it demonstrates the efficacy of abametapir lotion, which is currently pending FDA approval.”
Ken VanLuvanee, President and CEO, Facet Life Sciences, commented, “The recent publication of this manuscript is yet another example of the type of contributions the Facet team is making across the life sciences industry. It also showcases the level of expertise and the quality of continuing partnerships that we offer to our clients.”
The study was first published on July 12th, 2018. Pediatric Dermatology is distributed six times a year by Wiley Periodicals, Inc. Full text of the article can be found online here.
Facet Life Sciences is the leading provider of innovative development solutions (software and services) designed to help small teams get to and through the FDA©. Our Product Development Champions deliver expert nonclinical, CMC, and clinical regulatory services using cutting-edge technologies that speed product R&D efforts. Facet teams create and manage critical development documentation for some of the industry’s fastest growing, most innovative life sciences companies.